Substrate reduction therapy in three patients with Gaucher disease.
- Author:
Soo Hyun KIM
1
;
Eungu KANG
;
Yoon Myung KIM
;
Gu Hwan KIM
;
In Hee CHOI
;
Jin Ho CHOI
;
Han Wook YOO
;
Beom Hee LEE
Author Information
- Publication Type:Original Article
- Keywords: Gaucher disease; Miglustat
- MeSH: Acid Phosphatase; Adult; Biomarkers; Diagnosis; Diarrhea; Enzyme Replacement Therapy; Gaucher Disease*; Glucosylceramidase; Humans; Hypersensitivity; Lysosomal Storage Diseases; Platelet Count; Weight Loss
- From:Journal of Genetic Medicine 2016;13(2):72-77
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Gaucher disease (GD) is the most common lysosomal storage disease caused by beta-glucocerebrosidase (GBA) deficiency. Oral substrate reduction therapy with miglustat (Zavesca®) was approved for the treatment of adults with GD type 1, for whom enzyme replacement therapy (ERT) is unsuitable or not a therapeutic option. In this study, we report the effect of miglustat (Zavesca®) in three Korean GD patients. MATERIALS AND METHODS: Clinical findings comprising age at diagnosis, presenting signs, laboratory findings at diagnosis, GBA activity and mutations, and clinical courses of the three patients were reviewed. RESULTS: Miglustat was administered to three patients who reported allergic reactions during intravenous imiglucerase infusions. One patient withdrew after 15 months of miglustat administration owing to continuous elevation of disease biomarker levels (chitotriosidase, acid phosphatase, and angiotensin-converting enzyme). Poor adherence to medication was suspected but was denied by the patient. In the other two patients, platelet count and levels of hemoglobin and other biomarkers remained stable during miglustat administration. However, they suffered from severe diarrhea and weight loss, which led to miglustat discontinuation after 1 and 12 months of administration. CONCLUSION: Our study shows that although miglustat is suggested to GD patients as an alternative treatment to ERT, significant adverse reactions may lead to discontinuation of miglustat. In addition, it is difficult to monitor the drug adherence.
